Dr. Laura Alonso

Researchers at Weill Cornell Medicine have uncovered a novel route to stimulate the growth of healthy insulin-producing pancreatic beta cells in a preclinical model of diabetes. The findings hold promise for future therapeutics that will improve the lives of individuals with type 2 diabetes—a condition that affects more than half a billion people worldwide.

Dr. Laura Alonso, chief of the Division of Endocrinology, Diabetes and Metabolism and the Herbert J. and Ann L. Siegel Distinguished Professor of Medicine at Weill Cornell Medicine, has been selected to be a fellow of the Hedwig van Ameringen Executive Leadership in Academic Medicine (ELAM) Program at Drexel University College of Medicine.

COVID-19 may bring high risks of severe disease and death in many patients by disrupting key metabolic signals and thereby triggering hyperglycemia, according to a new study from researchers at Weill Cornell Medicine and NewYork-Presbyterian. 

Endocrinology Chief Dr. Laura Alonso—A specialist in diabetes research and treatment—is exploring ways to restore the body’s insulin production

Awards, honors, prizes and achievements for the month of July.

Dr. Laura Alonso has been named chief of the Division of Endocrinology, Diabetes and Metabolism at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center, effective Sept. 1. Dr. Alonso will also lead the Joan and Sanford I. Weill Center for Metabolic Health at Weill Cornell Medicine.